Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population (Q42195595)

18 October 2017

title

Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population (English)

1 reference

18 October 2017

1 reference

Jacob Atsmon

1

1 reference

18 October 2017

Yoseph Caraco

2

1 reference

18 October 2017

Sagit Ziv-Sefer

3

1 reference

18 October 2017

Dimitry Shaikevich

4

1 reference

18 October 2017

Ester Abramov

5

1 reference

18 October 2017

Inna Volokhov

6

1 reference

18 October 2017

Svetlana Bruzil

7

1 reference

18 October 2017

Kirsten Y Haima

8

1 reference

18 October 2017

Tanya Gottlieb

9

1 reference

18 October 2017

Tamar Ben-Yedidia

10

1 reference

18 October 2017

language of work or name

English

0 references

publication date

28 August 2014

1 reference

18 October 2017

1 reference

18 October 2017

volume

32

1 reference

18 October 2017

issue

44

1 reference

18 October 2017

page(s)

5816-5823

1 reference

Challenges for vaccination in the elderly.

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Biology of immune responses to vaccines in elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Antibody response to influenza vaccination in the elderly: a quantitative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Immune response to influenza vaccination in a large healthy elderly population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Immune response to influenza vaccination in an elderly population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Effectiveness of inactivated influenza vaccines in preventing influenza-associated deaths and hospitalizations among Ontario residents aged ≥ 65 years: estimates with generalized linear models accounting for healthy vaccinee effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Immunogenicity and safety of intradermal influenza vaccination in healthy older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Aging and impaired immunity to influenza viruses: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Inactivated influenza vaccines: recent progress and implications for the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Cell-mediated protection in influenza infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Interferon induction and increased natural killer-cell activity in influenza infections in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

T cell responses are better correlates of vaccine protection in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.031

10.1016/J.VACCINE.2014.08.031

7 January 2021

Identifiers

DOI

1 reference

18 October 2017

1 reference